share_log

Pyxis Oncology Announces FDA Clearance Of Two IND Applications

Pyxis Oncology Announces FDA Clearance Of Two IND Applications

Pyxis Oncology 宣布美国食品药品管理局批准两项 IND
Benzinga Real-time News ·  2022/12/01 06:48

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate

美国食品药品管理局批准了PYX-201的IND许可, 一种新的抗体药物偶联物(ADC)候选产品, 还有 PYX-106, 免疫疗法候选产品

Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors

PYX-201 和 PYX-106 的 1 期临床试验将评估特定实体瘤患者的安全性和抗肿瘤活性

Dual IND clearances represent achievement of significant 2022 milestones and executional pipeline advancement

双重IND许可代表着2022年重要里程碑的实现和执行渠道的进展

Cash runway extended into first half 2025

现金流延至2025年上半年

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发